Drugs / RCT1100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06633757 | Oct 2024 → Jun 2025 | primary ciliary dyskinesia | ReCode Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06600425 | Sep 2024 → Jun 2025 | primary ciliary dyskinesia | ReCode Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05737485 | Feb 2023 → Jul 2024 | primary ciliary dyskinesia | ReCode Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-20 | ReCode Therapeutics | Results ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients recodetx.com ↗
Data from ReCode’s RCT1100-103 Phase 1b trial across sites in Denmark, Germany, and the United States showed that 57% of patients achieved meaningful improvement in mucociliary clearance at 12 weeks. |
| 2024-06-27 | ReCode Therapeutics | Regulatory ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia recodetx.com ↗
Menlo Park, Calif. – June 27, 2024 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT1100 for the treatment of primary ciliary dyskinesia (PCD). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-20 | ReCode Therapeutics | ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients recodetx.com ↗ |
| 2024-06-27 | ReCode Therapeutics | ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia recodetx.com ↗ |
| 2023-03-15 | ReCode Therapeutics | ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia recodetx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RCT1100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06600425 ↗ |
| Action | Restore | “ciliary rescue” NCT06600425 ↗ |
| Modality | Messenger RNA (mRNA) | “RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer” NCT05737485 ↗ |
| Route | Inhaled | “administered via oral inhalation using nebulizer” NCT05737485 ↗ |